The phospholipase A2 pathway controls a synaptic cholesterol ester cycle and synapse damage.

The cellular prion protein (PrPC) acts as a scaffold protein that organises signalling complexes. In synaptosomes, the aggregation of PrPC by amyloid-ß (Aß) oligomers attracts and activates cytoplasmic phospholipase A2 (cPLA2), leading to synapse degeneration. The signalling platform is dependent on cholesterol released from cholesterol esters by cholesterol ester hydrolases (CEHs). The activation of cPLA2 requires cholesterol released from cholesterol esters by cholesterol ester hydrolases (CEHs), enzymes dependent upon platelet activating factor (PAF) released by activated cPLA2 This demonstrates a positive feedback system in which activated cPLA2 increased cholesterol concentrations, which in turn facilitated cPLA2 activation. PAF was also required for the incorporation of the tyrosine kinase Fyn and cyclooxygenase (COX)-2 into Aß-PrPC-cPLA2 complexes. As a failure to deactivate signalling complexes can lead to pathology, the mechanisms involved in their dispersal were studied. PAF facilitated the incorporation of acyl-coenzyme A:cholesterol acyltransferase (ACAT)-1 into Aß-PrPC-cPLA2-COX-2-Fyn complexes. The esterification of cholesterol reduced cholesterol concentrations, causing dispersal of Aß-PrPC-cPLA2-COX-2-Fyn complexes and the cessation of signalling. This study identifies PAF as a key mediator regulating the cholesterol ester cycle, activation of cPLA2 and COX-2 within synapses, and synapse damage.

The cholesterol ester cycle regulates signalling complexes and synapse damage caused by amyloid-ß.

Cholesterol is required for the formation and function of some signalling platforms. In synaptosomes, amyloid-ß (Aß) oligomers, the causative agent in Alzheimer's disease, bind to cellular prion proteins (PrPC) resulting in increased cholesterol concentrations, translocation of cytoplasmic phospholipase A2 (cPLA2, also known as PLA2G4A) to lipid rafts, and activation of cPLA2 The formation of Aß-PrPC complexes is controlled by the cholesterol ester cycle. In this study, Aß activated cholesterol ester hydrolases, which released cholesterol from stores of cholesterol esters and stabilised Aß-PrPC complexes, resulting in activated cPLA2 Conversely, cholesterol esterification reduced cholesterol concentrations causing the dispersal of Aß-PrPC complexes. In cultured neurons, the cholesterol ester cycle regulated Aß-induced synapse damage; cholesterol ester hydrolase inhibitors protected neurons, while inhibition of cholesterol esterification significantly increased Aß-induced synapse damage. An understanding of the molecular mechanisms involved in the dispersal of signalling complexes is important as failure to deactivate signalling pathways can lead to pathology. This study demonstrates that esterification of cholesterol is a key factor in the dispersal of Aß-induced signalling platforms involved in the activation of cPLA2 and synapse degeneration.

Glimepiride protects neurons against amyloid-ß-induced synapse damage.

Alzheimer's disease is associated with the accumulation within the brain of amyloid-ß (Aß) peptides that damage synapses and affect memory acquisition. This process can be modelled by observing the effects of Aß on synapses in cultured neurons. The addition of picomolar concentrations of soluble Aß derived from brain extracts triggered the loss of synaptic proteins including synaptophysin, synapsin-1 and cysteine string protein from cultured neurons. Glimepiride, a sulphonylurea used for the treatment of diabetes, protected neurons against synapse damage induced by Aß. The protective effects of glimepiride were multi-faceted. Glimepiride treatment was associated with altered synaptic membranes including the loss of specific glycosylphosphatidylinositol (GPI)-anchored proteins including the cellular prion protein (PrP(C)) that acts as a receptor for Aß42, increased synaptic gangliosides and altered cell signalling. More specifically, glimepiride reduced the Aß-induced increase in cholesterol and the Aß-induced activation of cytoplasmic phospholipase A2 (cPLA2) in synapses that occurred within cholesterol-dense membrane rafts. Aß42 binding to glimepiride-treated neurons was not targeted to membrane rafts and less Aß42 accumulated within synapses. These studies indicate that glimepiride modified the membrane micro-environments in which Aß-induced signalling leads to synapse damage. In addition, soluble PrP(C), released from neurons by glimepiride, neutralised Aß-induced synapse damage. Such observations raise the possibility that glimepiride may reduce synapse damage and hence delay the progression of cognitive decline in Alzheimer's disease.

Monoacylated Cellular Prion Proteins Reduce Amyloid-ß-Induced Activation of Cytoplasmic Phospholipase A2 and Synapse Damage.

Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by the accumulation of amyloid-ß (Aß) and the loss of synapses. Aggregation of the cellular prion protein (PrPC) by Aß oligomers induced synapse damage in cultured neurons. PrPC is attached to membranes via a glycosylphosphatidylinositol (GPI) anchor, the composition of which affects protein targeting and cell signaling. Monoacylated PrPC incorporated into neurons bound "natural Aß", sequestering Aß outside lipid rafts and preventing its accumulation at synapses. The presence of monoacylated PrPC reduced the Aß-induced activation of cytoplasmic phospholipase A2 (cPLA2) and Aß-induced synapse damage. This protective effect was stimulus specific, as treated neurons remained sensitive to α-synuclein, a protein associated with synapse damage in Parkinson's disease. In synaptosomes, the aggregation of PrPC by Aß oligomers triggered the formation of a signaling complex containing the cPLA2.a process, disrupted by monoacylated PrPC. We propose that monoacylated PrPC acts as a molecular sponge, binding Aß oligomers at the neuronal perikarya without activating cPLA2 or triggering synapse damage.